Central Serous Chorioretinopathy and Micropulse Laser Treatment

Recruiting now

Conditions studied: Central Serous Chorioretinopathy

In brief

To evaluate choroidal and choriocapillaris changes in patients with central serous chorioretinopathy, undergone sub threshold micropulse laser treatment, following any improvement with conservative therapy with Acetazolamide and/or Eplerenone

Key facts

Study ID

NCT06346405

Run by

Fondazione Policlinico Universitario Agostino Gemelli IRCCS

People needed

36

Starts

2023-05-31

Expected to finish

2027-05-31

Last updated by the study team

2025-09-23

Who can join

Age: 18 and older, up to 70. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Diagnosis of central serous chorioretinopathy (CSC) with no response to conservative therapy, consisted in Acetazolamide and Eplerenone after six months.
• Foveal serous retinal detachment for at least 6 months.
• Minimum age of 18 years old at the screening time
• Reading and comprehension skills of informed consent

You may not qualify if…

• Previous retinal treatment for CSC, except for Acetazolamide and Eplerenone
• No diffuse retinal epitheliopathy
• Other concomitant ocular diseases, such as age related macular degeneration, diabetic retinopathy, choroidal neovascularization
• Not controlled glaucoma with eyedrops, or advanced glaucoma
• Myopia or hypermetropia greater than 6 diopters
• Opacities of dioptric media
• Low quality of optical coherence tomography (OCT) and OCT-Angiography scans
• Low quality images of Fluorescein angiography and indocyanine green angiography
• No written consensus signed.

Where it is running

• Fondazione Policlinico Agostino Gemelli, IRCCS — Roma, R, Italy (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.